ZBIO
Zenas BioPharma, Inc.
Key Financials
Operating Income
$-383057000
↓ 133.7%
Net Income
$-377737000
↓ 140.6%
Revenue
$10.0M
↑ 100.0%
Total Assets
$383.6M
↑ 3.7%
EPS (Diluted)
$-8.44
↑ 29.0%
Total Liabilities
$141.5M
↑ 146.0%
Shareholders' Equity
$242.1M
↓ 22.5%
Operating Cash Flow
$-172333000.00
↓ 44.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| S-3ASR | 9/11/2026 | View on SEC |
| S-8 | 9/11/2026 | View on SEC |
| SCHEDULE 13G | 9/8/2026 | View on SEC |
| 3 | 9/8/2026 | View on SEC |
| SCHEDULE 13G/A | 9/8/2026 | View on SEC |
| 4 | 9/2/2026 | View on SEC |
| 3 | 9/2/2026 | View on SEC |
| SCHEDULE 13D/A | 8/19/2026 | View on SEC |
| 144 | 8/19/2026 | View on SEC |
| SCHEDULE 13D/A | 8/17/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ZBIO |
| Company Name | Zenas BioPharma, Inc. |
| CIK | 1953926 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 857-271-2954 |